原住民痴呆症的风险,保护性和生物标志物:系统审查
Huong X T Nguyen1,2, Kate Bradley1, Bridgette J McNamara3,4
1Department of Medicine, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|September 25, 2023
概括
痴呆症是全球土著人民面临的重大健康挑战. 识别可修改的风险和保护因素对于促进这些社区健康的衰老和认知功能至关重要.
科学领域:
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
- 老年学是一门学科.
背景情况:
- 痴呆症是全球土著人口日益严重的健康问题.
- 对于这些社区中痴呆的驱动因素和保护因素的了解有限.
结论:
- 了解可修改因素和生物标志物对于开发有效的,基于实力的战略至关重要.
- 这些策略可以支持土著人民的健康衰老和认知福祉.
相关概念视频
Dementia
131
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
131
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


